<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of 12 Weeks of Treatment with RN316 (PF-04950615) in Hypercholesterolemic Subjects on High and Maximal Dose Statins</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Results from two Phase 2 trials indicate that intravenous infusions of RN316, a humanized IgG2?a monoclonal antibody that inhibits proprotein convertase subtilisin kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol in hypercholesterolemic subjects already on high to maximal doses of statins.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>